Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abicipar Pegol in Neovascular Age-related Macular Degeneration (SEQUOIA)
NCT02462486Phase 3Completed
- Sponsor
- Allergan
- Start
- Jun 2015
- Primary completion
- Apr 2018
- Modality
- Carrier/Scaffold Proteins
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of abicipar pegol in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Allergan. Primary endpoint: Percentage of Participants With Stable Vision at 52 weeks. Started Jun 2015; status: completed.
02
Drugs
abicipar pegol
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02462486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462486.